Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Latest Results: Q2 2015 Quarterly
- Oct 2 2015 8:00 AM EDT Cancer Genetics Receives Bankruptcy Court Approval to Purchase Los Angeles-Based Response Genetics, Inc.
- Sep 17 2015 4:00 AM EDT Cancer Genetics, Inc. to Report Results From Two Independent Studies at the 30th International Papillomavirus Conference & Clinical and Public Health Workshops (HPV 2015)
- Sep 8 2015 1:52 PM EDT UPDATE -- Cancer Genetics, Inc. Increases Access to Proprietary Diagnostics Tests as Part of New Agreement With Blue Cross Blue Shield of Illinois
Cancer Genetics, Inc.
201 Route 17 North
Rutherford, NJ 07070
Life Science Advisors LLC